Rise and shine, everyone, another busy day is on the way. Most days are busy, though, yes? So why should today be an exception? There is always so much to keep track of and so much to do. Rather than resist, why not embrace the inevitable with a nice cup of stimulation? We are savoring chocolate cherry decadence this morning and invite you to join us. Remember, be nice to your neurons. Meanwhile, here are some items of interest to provide an extra boost. Hope all goes well and do keep in touch …

Just months after lawmakers on the House Energy and Commerce Committee lavished praise on each other for passing a slew of drug pricing bills, committee efforts to deal with the issue are quickly descending into partisan chaos, STAT says. At a hearing on Wednesday, Republicans accused Democrats of sabotaging bipartisan efforts to lower the cost of prescription drugs. At times, both parties were tripping over themselves to lob attacks and complain. And at one point, they were openly bickering about their respective speaking time.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Ah, if the US would but imitate the approach of Iran? (Somehow one thinks it would need to be framed differently but …)

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy